Loading...
XASECPHI
Market cap3mUSD
Dec 23, Last price  
0.18USD
1D
3.45%
1Q
-17.96%
Jan 2017
-30.77%
Name

China Pharma Holdings Inc

Chart & Performance

D1W1MN
XASE:CPHI chart
P/E
P/S
0.49
EPS
Div Yield, %
0.00%
Shrs. gr., 5y
-4.94%
Rev. gr., 5y
-10.68%
Revenues
7m
-13.48%
23,2758,657,81321,843,26233,186,32450,968,66061,696,62074,388,18081,166,73954,507,04932,806,67722,133,86620,351,63015,570,51413,212,31412,330,68710,923,93610,866,4499,641,9258,104,0927,011,299
Net income
-3m
L-69.88%
-504,2923,799,5508,587,08612,819,53317,833,65020,233,04923,414,34719,269,6424,617,659-20,008,049-26,047,375-15,405,518-9,182,624-19,277,565-10,750,167-21,023,762-3,160,936-3,941,477-10,221,635-3,078,818
CFO
-700k
L+70.84%
-35,812-449,095-1,736,3332,801,8986,543,26010,668,9267,785,4875,237,3243,643,8208,595,8154,572,3723,350,0602,895,708841,2161,256,992608,312-42,260-249,838-409,545-699,686

Profile

China Pharma Holdings, Inc. develops, manufactures, and markets generic and branded pharmaceutical, and biochemical products primarily to hospitals and private retailers in the People's Republic of China. The company offers products in the form of dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions. Its products include Cerebroprotein Hydroloysate injection to treat memory decline and attention deficit; Gastrodin injection for tiredness, loss of concentration, poor sleep, and traumatic syndromes of the brain; Propylgallate and Ozagrel Sodium to treat cerebral thrombosis, coronary heart disease, and after surgery complications; Alginic Sodium Diester injection for ischemic heart, cerebrovascular, and high lipoprotein blood diseases; Bumetanide injection to treat edema diseases; and Candesartan for hypertension. It also provides Roxithromycin dispersible tablets for pharyngitis and tonsillitis; Cefaclor dispersible tablets for tympanitis, lower respiratory tract infection, urinary tract infections, and skin/skin tissue infection; Cefalexin capsules for acute tonsillitis; Andrographolide for sore throat caused by upper respiratory tract infection; Clarithromycin granules and capsules; and Naproxen Sodium and PseudophedrineHydrochlorida sustained release tablets. In addition, the company offers Hepatocyte growth-promoting factor, Tiopronin, Compound Ammonium Glycyrrhetate S, and Omeparzole for the treatment of digestive diseases. Further, it provides Vitamin B6 injection; Granisetron Hydrochloride injection to treat nausea and vomiting caused by radiotherapy and chemotherapy during the treatment of malignant tumors; Noni Enzyme, a food supplement; sanitizers; and masks. The company offers its products through distributors, as well as through its network of 16 sales offices and approximately 1,000 sales representatives. China Pharma Holdings, Inc. was founded in 1993 and is based in Haikou, the People's Republic of China.
IPO date
Feb 15, 2000
Employees
234
Domiciled in
CN
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
7,011
-13.48%
8,104
-15.95%
9,642
-11.27%
Cost of revenue
9,779
11,747
12,758
Unusual Expense (Income)
NOPBT
(2,768)
(3,643)
(3,116)
NOPBT Margin
Operating Taxes
6,249
542
Tax Rate
NOPAT
(2,768)
(9,892)
(3,658)
Net income
(3,079)
-69.88%
(10,222)
159.34%
(3,941)
24.69%
Dividends
Dividend yield
Proceeds from repurchase of equity
1,650
1,707
BB yield
-403.02%
-338.69%
Debt
Debt current
3,182
8,757
7,194
Long-term debt
1,569
40
5,424
Deferred revenue
(5,250)
Other long-term liabilities
5,250
Net debt
3,328
6,768
7,758
Cash flow
Cash from operating activities
(700)
(410)
(250)
CAPEX
(12)
(402)
(438)
Cash from investing activities
(12)
(402)
(438)
Cash from financing activities
73
(1,770)
4,598
FCF
(1,941)
(5,618)
(2,357)
Balance
Cash
1,424
2,030
4,859
Long term investments
Excess cash
1,073
1,625
4,377
Stockholders' equity
(27,828)
(24,564)
(19,627)
Invested Capital
39,916
36,545
37,292
ROIC
ROCE
EV
Common stock shares outstanding
3,384
5,257
4,613
Price
0.12
26.17%
0.10
-80.13%
0.48
8.25%
Market cap
409
-18.79%
504
-77.35%
2,226
14.47%
EV
3,737
7,272
9,985
EBITDA
(14)
(942)
(28)
EV/EBITDA
Interest
334
424
542
Interest/NOPBT